The European Centre for Disease Prevention and Control was asked by the European Commission to assess the risk involved in changing the testing requirements for HIV (human immunodeficiency virus), hepatitis B virus (HBV), and hepatitis C virus (HCV) with regard to the quality and safety of non-partner semen donations.
The joint annual influenza surveillance meeting by ECDC and the WHO Regional Office for Europe took place on 6 - 8 June 2018 in Copenhagen, Denmark. Invited participants were epidemiological and virological surveillance experts nominated by national health authorities as well as representatives from international institutions, covering the 53 countries of the EU/EEA and the WHO European region. The meeting was by invitation only.
After the EPIS FWD notification of a cluster of hepatitis A cases infected with two distinct strains in several EU/EEA countries, this risk assessment presents the early findings of this multi-country hepatitis A outbreak and sets out initial options for response.
In order to explore whether the current capacity for EU/EEA-wide molecular characterisation for surveillance of HBV and HCV is sufficient to be feasible and what gaps need to be addressed, a survey of EU/EEA Member States was conducted to assess their laboratory capacity and needs in relation to the molecular characterisation of hepatitis B and C.
The key objective of this meeting was to verify the rationale and objectives of molecular typing for surveillance of hepatitis E virus (HEV) through the hepatitis E network (HEVnet). The workshop reviewed HEVnet as a tool for molecular surveillance of HEV in Europe.
ECDC monitors and reports on influenza transmission and virus circulation in Europe on a weekly basis throughout the flu season, in collaboration with WHO Regional Office for Europe, in the report Flu News Europe.
The ERLI-Net sub-network of reference laboratories of the European Influenza Surveillance Network carries out virological surveillance of human influenza in the EU/EEA through the EISN timely reporting mechanism and strengthening laboratory capacity for influenza virus detection, antiviral susceptibility testing and typing.